After America’s Modern Inc., the results of the Corona vaccine at Oxford University, UK, have also been successful. Oxford’s drug also develops immunity against the virus in volunteers. Oxford scientists are not only confident of the complete success of the vaccine ChAdOx1 nCoV-19 (now AZD1222) but are also up to 80% confident that the vaccine will be available by September. The Oxford vaccine will be produced by AstraZeneca.
Immunity seen in volunteers
The results of the Oxford trial have not yet been officially announced and are expected to appear in ‘The Lancet’ on Thursday. Its trial was done on 15 volunteers and in the coming weeks, it will be tested on around 200-300 more volunteers. It has been claimed that people who were given the vaccine in the Oxford trial have been found to develop antibodies and white blood cells (T-Cells), which can help their bodies develop immunity when they are infected with the virus.
Tests were successful, trials on thousands
The special thing is that usually antibodies are produced through the vaccine, but in the Oxford vaccine, antibodies are produced as well as white blood cells (killer T-cells). If successful without any loss in the initial trials, thousands of people will be moved to test it. Trials of this vaccine include 8,000 people in Britain and 6 thousand people in Brazil and South Africa. The Oxford vaccine was first tested on humans in Britain.
Moderna’s vaccine is also successful
Earlier, the American company Moderna’s Coronavirus Vaccine was completely successful in its first trial. The study, published in the New England Journal of Medicine, says that the first test of this vaccine on 45 healthy people has had very good results. This vaccine developed antibodies for a fight from corona within each individual. This first test included 45 such people who were healthy and their age was between 18 and 55 years.
No major side effects
Legendary drug maker Moderna is now preparing for a late-stage trial of the Coronavirus vaccine. According to the company, the trial can be started around July 27. There is no significant side effect due to which the vaccine trial should be stopped. After giving three doses of vaccine during the trial, half of the people had mild fatigue, body ache, and headache. About 40 percent of people experienced mild fever after giving the vaccine.